International Journal of Gynecological Cancer

The role of surgery in recurrent ovarian cancer
pp. 195-198(4)
Authors: PFISTERER,; HARTER,; CANZLER,; RICHTER,; JACKISCH,; HAHMANN,; HASENBURG,; BURGES,; LOIBL,; GROPP,; HUOBER,; FINK,; BOIS,

What is the role of conservative primary surgical management of epithelial ovarian cancer: the United States experience and debate
pp. 199-205(7)
Authors: MONK,; DiSAIA,

Role of conservative surgery in ovarian cancer: the European experience
pp. 206-211(6)
Authors: COLOMBO,; PARMA,; LAPRESA,; MAGGI,; PIANTANIDA,; MAGGIONI,

Standard treatment in advanced ovarian cancer in 2005: the state of the art
pp. 212-220(9)
Author: BOOKMAN,

First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB–IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival
pp. 221-221(1)
Authors: KRISTENSEN,; VERGOTE,; STUART,; delCAMPO,; KÆRN,; BAEKELANDT,; LOPEZ,; HIRTE,; AAVALL-LUNDQVIST,; LORENZ,; CERAR,

Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages IIB–IV. Results of a randomized AGO-GINECO GCIG Intergroup phase III trial
pp. 222-223(2)
Authors: PUJADE-LAURAINE,; BOIS,; GOUPIL,; ROCHON,; MÖBUS,; WEBER,; OLBRICHT,; NITZ,; WARM,; RICHTER,

Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC
pp. 224-225(2)
Authors: BOIS,; SEHOULI,; LUND,; JOLY,; HUOBER,; JENSEN,; LEVY,; HEILMANN,; BOMAN,; HARDY-BESSARD,; BURGES,; MÄENPÄÄ,; PUJADE-LAURAINE,; PFISTERER,; GROPP,; STAEHLE,; WIMBERGER,; JACKISCH,; SCHMALFELDT,; BELAU,; LOIBL,; WOLLSCHLAEGER,; CANZLER,; ROCHON,

“Dose dense” chemotherapy in ovarian cancer
pp. 226-232(7)
Author: VASEY,

What is the role of dose-dense therapy?
pp. 233-240(8)
Authors: BURG,; van derGAAST,; VERGOTE,; BURGER,; vanDOORN,; deWIT,; STOTER,; VERWEIJ,

Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy
pp. 241-246(6)
Authors: GONZÁLEZ-MARTÍN,

Randomized single-agents trials in recurrent epithelial ovarian cancer
pp. 247-251(5)
Authors: SESSA,; MARSONI,

New agents for the treatment of ovarian cancer: the next generation
pp. 252-257(6)
Authors: DUPONT,; AGHAJANIAN,; SABBATINI,; SPRIGGS,

Trial design for testing new therapies in ovarian cancer
pp. 258-265(8)
Author: EISENHAUER,

Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets
pp. 266-273(8)
Authors: BOYCE,; KOHN,

New tumor markers: CA125 and beyond
pp. 274-281(8)
Authors: BAST,; BADGWELL,; LU,; MARQUEZ,; ROSEN,; LIU,; BAGGERLY,; ATKINSON,; SKATES,; ZHANG,; LOKSHIN,; MENON,; JACOBS,

Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease
pp. 282-290(9)
Authors: ZOODSMA,; NOLTE,; SCHIPPER,; OOSTEROM,; van derSTEEGE,; deVRIES,; teMEERMAN,; van derZEE,

Is there still a role for hormonal therapy?
pp. 291-297(7)
Author: BOOKMAN,

Ovarian cancer: is the news good enough?
pp. 298-306(9)
Author: POVEDA,